Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeremy A Squire

Showing results (141-150 of 167) with videos related to

Pageof 17
Sort By:
Journal of Neurosurgery|October 7, 2005
Comparative genomic hybridization analysis of pediatric adamantinomatous craniopharyngiomas and a review of the literatureMaisa Yoshimoto, Sílvia Regina Caminada de Toledo, Nasjla Saba da Silva, et al.
Translational Oncology|February 13, 2013
The 16p13.3 (PDPK1) Genomic Gain in Prostate Cancer: A Potential Role in Disease ProgressionKhalil A Choucair, Karl-Philippe Guérard, Joshua Ejdelman, et al.
The Journal of Pathology|April 30, 2009
PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancerKanishka Sircar, Maisa Yoshimoto, Federico A Monzon, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 5, 2014
PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomyTamara L Lotan, Filipe Lf Carvalho, Sarah B Peskoe, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 5, 2020
High throughput assessment of biomarkers in tissue microarrays using artificial intelligence: PTEN loss as a proof-of-principle in multi-center prostate cancer cohortsStephanie A Harmon, Palak G Patel, Thomas H Sanford, et al.
Frontiers in Oncology|November 15, 2023
Identification of tumor-agnostic biomarkers for predicting prostate cancer progression and biochemical recurrenceWilliam Lautert-Dutra, Camila M Melo, Luiz P Chaves, et al.
Cancers|April 27, 2024
Investigating the Role of <i>SNAI1</i> and <i>ZEB1</i> Expression in Prostate Cancer Progression and Immune Modulation of the Tumor MicroenvironmentWilliam Lautert-Dutra, Camila Morais Melo, Luiz Paulo Chaves, et al.
European Journal of Medical Genetics|September 15, 2010
Cytogenetic molecular delineation of a terminal 18q deletion suggesting neo-telomere formationLeslie Domenici Kulikowski, Maisa Yoshimoto, Fernanda Teixeira da Silva Bellucco, et al.
Cancer Genetics|June 12, 2012
Multiple CDK/CYCLIND genes are amplified in medulloblastoma and supratentorial primitive neuroectodermal brain tumorMeihua Li, Will Lockwood, Maria Zielenska, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2008
Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21Chang-Qi Zhu, Gilda da Cunha Santos, Keyue Ding, et al.
Pageof 17

Showing results (141-150 of 167) with videos related to

Sort By:
Pageof 17
Journal of Neurosurgery|October 7, 2005
Comparative genomic hybridization analysis of pediatric adamantinomatous craniopharyngiomas and a review of the literatureMaisa Yoshimoto, Sílvia Regina Caminada de Toledo, Nasjla Saba da Silva, et al.
Translational Oncology|February 13, 2013
The 16p13.3 (PDPK1) Genomic Gain in Prostate Cancer: A Potential Role in Disease ProgressionKhalil A Choucair, Karl-Philippe Guérard, Joshua Ejdelman, et al.
The Journal of Pathology|April 30, 2009
PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancerKanishka Sircar, Maisa Yoshimoto, Federico A Monzon, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 5, 2014
PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomyTamara L Lotan, Filipe Lf Carvalho, Sarah B Peskoe, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 5, 2020
High throughput assessment of biomarkers in tissue microarrays using artificial intelligence: PTEN loss as a proof-of-principle in multi-center prostate cancer cohortsStephanie A Harmon, Palak G Patel, Thomas H Sanford, et al.
Frontiers in Oncology|November 15, 2023
Identification of tumor-agnostic biomarkers for predicting prostate cancer progression and biochemical recurrenceWilliam Lautert-Dutra, Camila M Melo, Luiz P Chaves, et al.
Cancers|April 27, 2024
Investigating the Role of <i>SNAI1</i> and <i>ZEB1</i> Expression in Prostate Cancer Progression and Immune Modulation of the Tumor MicroenvironmentWilliam Lautert-Dutra, Camila Morais Melo, Luiz Paulo Chaves, et al.
European Journal of Medical Genetics|September 15, 2010
Cytogenetic molecular delineation of a terminal 18q deletion suggesting neo-telomere formationLeslie Domenici Kulikowski, Maisa Yoshimoto, Fernanda Teixeira da Silva Bellucco, et al.
Cancer Genetics|June 12, 2012
Multiple CDK/CYCLIND genes are amplified in medulloblastoma and supratentorial primitive neuroectodermal brain tumorMeihua Li, Will Lockwood, Maria Zielenska, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2008
Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21Chang-Qi Zhu, Gilda da Cunha Santos, Keyue Ding, et al.
Pageof 17